Find Academic Supervisors

• Diabetes Research
• Biophysics
• Bioengineering
• +4 more

Richard Benninger, PhD, serves as Assistant Professor at the University of Colorado Anschutz Medical Campus School of Medicine with joint appointments in Bioengineering and Pediatrics. He directs the Advanced Light Microscopy core facility and leads a multidisciplinary research program focused on diabetes mechanisms. Education: PhD, Imperial College of Science, Technology and Medicine (2006) Research Focus: The Benninger lab applies engineering principles to study pancreatic islets of Langerhans, investigating systems biophysics in diabetes, gap junction plasticity , cell heterogeneity , and advanced imaging techniques . Their work bridges optical microscopy , ultrasound imaging , and biophysical modeling to develop diabetes diagnostics and therapeutics targeting hormone release mechanisms. Publication Trends: Analysis of 15 recent publications reveals consistent focus on islet multicellular dynamics (73% of articles), gap junction regulation (60%), and imaging technology development (47%). Temporal trends show increasing emphasis on human islet studies (2017-2020) and translational applications for type 1 diabetes diagnostics. Scientific Awards: No awards were documented in the provided materials. Academic Service: Benninger actively contributes to diabetes research through the American Diabetes Association and Biophysical Society memberships. The text contains no information regarding graduate student mentorship or grant funding. Research Infrastructure: The Benninger lab operates as a collaborative engineering-medicine unit centered around the Advanced Light Microscopy core. Their technical capabilities integrate two-photon microscopy , calcium imaging , and computational modeling to analyze islet function across molecular, cellular, and tissue scales in both mouse and human models.

Jacques LuxView profile

Researcher

• Theranostics
• Nanomedicine
• Ultrasound Imaging
• +12 more

Jacques Lux is a researcher in the Department of Radiology at the University of Texas Southwestern Medical Center, where he contributes to the Translational Research in Ultrasound Theranostics (TRUST) program. His work bridges chemistry, materials science, and biomedical imaging, with a focus on developing next-generation diagnostic and therapeutic agents. Education: PhD in Chemistry, University of Strasbourg, under Nobel laureate Jean-Pierre Sauvage Postdoctoral training at Faculty of Pharmacy, Strasbourg Postdoctoral research at Scripps Research Institute (La Jolla, CA) Postdoctoral and Research Scientist roles at UCSD Dr. Lux's research focuses on theranostics , particularly the design of activatable ultrasound agents that enable both cancer detection and targeted therapy through drug release or high-intensity focused ultrasound. His work also encompasses stimuli-responsive nanomaterials , including light- and enzyme-activatable systems, and the development of high-relaxivity MRI contrast agents using nanogel platforms. These efforts aim to improve imaging specificity, reduce toxicity, and enable image-guided interventions. The 15 most recent publications highlight a strong trend in multimodal imaging , nanoparticle engineering , and translational biomedical applications . Key themes include ultrasound-triggered therapies, oxygen-generating nanoparticles for hypoxia relief, biosensors for infection detection, and light-responsive drug delivery systems. The research integrates supramolecular chemistry, polymer science, and clinical imaging to create smart, responsive platforms for precision medicine. Scientific Awards: No awards explicitly mentioned in the provided text. Dr. Lux has been actively involved in research grants and collaborative projects, particularly in the development of nanoparticle-based theranostic systems and image-guided cancer therapies . His collaborations span chemistry, radiology, and bioengineering, often involving translational studies aimed at clinical application. He has contributed to the design of novel contrast agents, enzyme-loaded nanoparticles, and activatable probes, suggesting sustained funding from biomedical research agencies. He is a key member of the TRUST program at UT Southwestern, a multidisciplinary team focused on advancing ultrasound theranostics. His lab likely involves a team of postdoctoral researchers, graduate students, and engineers working on nanoparticle synthesis, in vivo imaging, and preclinical validation of novel agents. The emphasis on translational research indicates strong institutional and possibly industry partnerships.

• Material Science
• Nanotechnology
• Peptide Chemistry
• +3 more

Jani Seitsonen serves as a Senior Scientist and Staff Scientist at OtaNano, Aalto University, Espoo, Finland. With over 100 research publications spanning 2013-2025, his work centers on nanotechnology and material science, specializing in peptide-based self-assembly, nanostructure characterization, and functional nanomaterial development for biomedical and environmental applications. His core research integrates material science, nanotechnology, and peptide chemistry to investigate lipopeptide nanostructures, antimicrobial systems, and nanomaterials for drug delivery. Key methodologies include transmission electron microscopy and small-angle X-ray scattering, enabling precise analysis of nanoparticle formation, surface dynamics, and molecular interactions in contexts ranging from wound healing to cancer therapy. This interdisciplinary approach bridges chemistry, biophysics, and biomedical engineering to create responsive nanosystems. Recent publications (2024-2025) demonstrate a pronounced shift toward biomedical applications, including antimicrobial peptide design, self-adjuvanting cancer vaccines, and tumor-targeting microbubbles, while maintaining strong environmental applications like pesticide detection. These works consistently leverage peptide amphiphilicity and chirality to engineer nanostructures with tunable disassembly properties, highlighting his focus on functional precision at the molecular level. No scientific awards were mentioned in the available information. There is no available information regarding students advised or research grants obtained by Dr. Seitsonen. As a core researcher at OtaNano—a national micro- and nanotechnology infrastructure—Seitsonen operates within interdisciplinary teams specializing in nanocharacterization and biomaterial synthesis. His collaborations span international institutions including the University of Reading and University of Helsinki, with recent work involving hydrophobin engineering, peptide conjugation, and microbubble development for targeted therapeutic delivery.

• Biomedical Engineering
• Ultrasound Imaging
• Magnetic Nanoparticles
• +3 more

Maria Evertsson serves as an Associate researcher and Postdoctoral fellow in the Division of Biomedical Engineering at Lund University's Faculty of Engineering. She actively contributes to the LTH Profile Area: Engineering Health and LU Profile Area: Light and Materials, focusing on translational medical technology development. Her pioneering research centers on magnetomotive ultrasound (MMUS), which detects magnetic nanoparticles by analyzing induced motion from time-varying magnetic fields. This technique overcomes conventional ultrasound limitations in nanoparticle visualization, enabling targeted disease detection like cancer tumors through advanced data algorithms that superimpose magnetomotive displacement as color-coded overlays on B-mode images. Her work integrates biomedical engineering, medical imaging, and nanotechnology to create cost-effective, real-time diagnostic solutions. Recent publications (2022-2025) demonstrate concentrated expertise in ultra-high frequency ultrasound applications for pediatric gastrointestinal diagnostics, particularly Hirschsprung's disease. Key contributions include specialized rectal ultrasound probes, bowel wall morphometric analysis tools, and magnetomotive techniques for lymph node imaging, establishing her as a leader in ultrasound-based pediatric diagnostics. Dr. Evertsson currently leads a Swedish Research Council-funded project (2024-2028) developing combined ultrasound-spectroscopy platforms for diagnosing pediatric bowel disorders, which has attracted significant media attention. She has supervised one research project and maintains active collaborations across international networks, as evidenced by her co-authorship with researchers from multiple countries. Within Lund University's Biomedical Engineering research group, she collaborates on interdisciplinary projects advancing medical imaging technologies, particularly through the Engineering Health profile area where her MMUS innovations show promise for clinical translation in cancer detection and pediatric diagnostics.

Mehdi RazaviView profile

Associate Professor

• Cardiac Electrophysiology
• Atrial Fibrillation
• Medical Device Innovation
• +3 more

Dr. Mehdi Razavi is an Associate Professor of Medicine-Cardiology at Baylor College of Medicine and Director of the Electrophysiology Clinical Research & Innovations program at the Texas Heart Institute. He holds clinical appointments at multiple institutions including CHI St. Luke's Health and serves as an Editorial Consultant for the Texas Heart Institute Journal . With board certifications in Internal Medicine, Cardiovascular Disease, and Clinical Cardiac Electrophysiology, Dr. Razavi bridges clinical practice with cutting-edge research. Education: MD from Medical College of Pennsylvania (1995), Residency and Fellowships at Mayo Graduate School of Medicine (1998-2002) Academic Affiliations: Baylor College of Medicine, Texas Heart Institute, Rice University, University of Houston, Texas A&M University, UCLA His research focuses on cardiac electrophysiology , atrial fibrillation , and biomedical device innovation . He has pioneered technologies like battery-less pacemakers , carbon nanotube fibers , and photoacoustic lesion mapping , with 18 patents to his name. Collaborations with engineering teams at Rice and Texas A&M drive his work in clinical cardiac electrophysiology and device development . Recent publications highlight his expertise in machine learning for arrhythmia detection, graphene-based nanomaterials for cardiac repair, and ethanol ablation techniques. Notably, his 2024 JMIR Mental Health study on stress monitoring and 2024 Sci Rep work on photoacoustic cardiac imaging demonstrate interdisciplinary innovation. Scientific Awards: Texas Super Doctors (2024, 2023, 2022, 2021) Robert J. Hall Outstanding Cardiology Faculty Teaching Award (2006, 2013) Texas Heart Institute EP Teaching Attending of the Year (2019) Pfizer Award for Electrophysiology Training (2002) Dr. Razavi leads the TMC Biodesign Program Mentorship and maintains active clinical trial participation. His work spans biomaterials , cardiac device development , and machine learning diagnostics , with a strong emphasis on translational research from bench to bedside. As a founder of multiple medical device startups, he drives commercialization of cardiovascular innovations .

• Drug Delivery
• Pharmaceutics
• Vaccine Formulation
• +3 more

Dr. Anil Vangala is a Senior Lecturer in Pharmaceutics at Kingston University's School of Life Sciences, Pharmacy and Chemistry, Department of Pharmacy, where he has served since 2007. He concurrently acts as Course Leader for MSc Pharmaceutical Science programs (including Management Studies and Professional Placement pathways) and serves as external examiner for Liverpool John Moores University's MSc in Cosmetic Science program. His academic foundation includes a PhD from Aston University (2006) supervised by Professor Yvonne Perrie, an M.Pharmacy from The Tamil Nadu Dr. M.G.R. Medical University (2000), and a B.Pharmacy from Gulbarga University (1997). He holds a Postgraduate Certificate in Teaching and Learning in Higher Education (2013) and was awarded Senior Fellow of the Higher Education Academy (2020). Dr. Vangala's research centers on advanced drug delivery systems using lipid and polymer-based particulate carriers for vaccines, therapeutic peptides, and ocular therapeutics. His work spans liposome/niosome formulation for vaccine adjuvants, oral delivery of biologics, and trigger-responsive ophthalmic gels. He leads a multidisciplinary research team investigating nanoparticle systems for cancer therapy, diabetes management, and ocular drug delivery. His 12 publications from 2004-2023 reveal consistent innovation in pharmaceutics, with recent work focusing on chitosan hydrogels for cancer therapy and non-invasive insulin delivery, while maintaining foundational contributions to vaccine adjuvant systems and ocular drug permeation studies. His scientific recognition includes: Senior Fellow of the Higher Education Academy (2020) Dr. Vangala actively mentors PhD and master's students while serving as thesis examiner and journal reviewer for leading publications including International Journal of Pharmaceutics. He contributes to academic governance as topical advisory panel member for Pharmaceutics journal (IF: 5.875) and as Race Equality Charter self-assessment team member at Kingston University. His research team maintains active projects in nanoparticle formulation and drug delivery optimization, with recent focus on polymeric systems for targeted cancer therapy and diabetes management.

• Ultrasound Imaging
• Medical Engineering
• Photoacoustic Imaging
• +5 more

Professor Georg Schmitz is a distinguished academic in the field of medical engineering and ultrasound imaging at Ruhr-University Bochum, Germany. He holds the chair for medical engineering within the Faculty for Electrical Engineering and Information Technology and has served as Dean of this faculty from 2009 to 2012. Since 2014, he has been a member of the Senate of Ruhr-University Bochum. Prof. Schmitz received his Dipl.-Ing. degree in 1990 and Dr.-Ing. degree in 1995 in electrical engineering from Ruhr-Universität Bochum. Prior to his current position, he worked as a Principal Scientist at Philips Research Laboratories from 1995 to 2001 and served as Professor for Medical Engineering at the University of Applied Science Koblenz from 2001 to 2004. His research primarily focuses on ultrasound imaging, with current projects investigating ultrasound contrast media detection and characterization, novel beamforming and nonlinear reconstruction methods, and photoacoustic imaging. Prof. Schmitz is particularly known for his work in super-resolution ultrasound, ultrasound localization microscopy, and the application of deep learning techniques to medical ultrasound imaging. His recent publications demonstrate significant advancements in microvascular imaging, cancer diagnostics, and image reconstruction algorithms. Prof. Schmitz's research output shows a clear trajectory toward integrating artificial intelligence with traditional ultrasound techniques, with numerous publications focusing on deep learning applications for image enhancement, needle localization, and super-resolution imaging. His work bridges theoretical signal processing with practical clinical applications, particularly in oncology and microcirculation imaging. Senior member of the IEEE Member of the Acoustical Society of America (ASA) Member of the German Association of Electrical Engineers (VDE) Member of WFUMB, EFSUMB, and DEGUM Former associate editor of IEEE Transactions of Ultrasonics, Ferroelectrics, and Frequency Control (15+ years) Member of Editorial Advisory Board of Ultrasound in Medicine and Biology Prof. Schmitz has played significant leadership roles in the international ultrasound community, serving as vice chair (medical ultrasound) of the IEEE International Ultrasonics Symposium technical program committee from 2013-2015, and as technical program chair for the symposium in Washington, D.C. (2017) and Venice (2022). His extensive collaborations with researchers including S. Dencks, T. Lisson, and M. Fouad have resulted in numerous high-impact publications spanning ultrasound technology, medical diagnostics, and imaging algorithms. His laboratory focuses on advancing ultrasound localization microscopy techniques and developing novel approaches for clinical applications, particularly in cancer imaging and treatment monitoring. The team's work on microbubble technology, photoacoustic imaging, and AI-enhanced ultrasound demonstrates a comprehensive approach to solving complex medical imaging challenges.

Grégory BeauneView profile

Research Fellow

• Nanoparticle Engineering
• Soft Matter Physics
• Biomaterials
• +2 more

Grégory Beaune is a Research Fellow in the Department of Applied Physics at Aalto University, specializing in active matter and nanotechnology. His research develops nanomaterials for biomedical applications using advanced physical principles. Key research areas include: Nanoparticle-based drug delivery systems Protein condensate behavior Ferrofluid applications Functional nanomaterial design Recent publications focus on echogenic microbubbles for tumor targeting and dynamics of biomolecular condensates. His work bridges fundamental physics with biomedical innovation.

• Medicinal Inorganic Chemistry
• Metal-Based Anticancer Agents
• Enzyme Inhibitors
• +5 more

Dr. Darren Griffith is a Senior Lecturer in the Department of Chemistry at Royal College of Surgeons in Ireland (RCSI). He holds a BSc (2000) and PhD (2004) in Medicinal Chemistry from University College Dublin and RCSI, respectively. His career includes postdoctoral research at Dublin City University (2004–2005) and RCSI (2006–2010), before becoming a Lecturer (2010) and Senior Lecturer (2018). His research focuses on medicinal inorganic chemistry, particularly metal-based complexes for anticancer therapies, enzyme inhibition, antibacterial agents, and antileishmanial treatments. Grants include SFI-funded projects on gallium formulations (2025), platinum-PROTACs (2022–2027), and targeted cancer therapies. He teaches in medical and pharmacy programs, including the International Medical Commencement Programme and MPharm courses. His work spans 49 publications, emphasizing platinum drug design, metallodrugs, and drug delivery systems.

• Medical Imaging
• Neurology
• Neonatal Brain Injury
• +4 more

Marius Widerøe is the Director of NTNU Health & Life Science and an Associate Professor of Magnetic Resonance (MR) at NTNU's Faculty of Medicine and Health Sciences. He leads strategic initiatives in health and life science research, emphasizing interdisciplinary collaboration and innovation. Previously, he managed NTNU's MR Core Facility and led Norway’s NORMOLIM research infrastructure, part of Euro-BioImaging. His academic roles include teaching MR techniques in PhD/Master programs. Education: Medical Doctor (2003), PhD in Clinical Medicine (2012) from NTNU, focusing on preclinical MR of neonatal brain injury. Research interests center on MR imaging applications in neuroscience, particularly neonatal brain injury, Alzheimer's disease, and nanoparticle-based therapies. He explores metabolic pathways in brain injuries and translational imaging techniques for early disease detection. Recent publications highlight advancements in MRI contrast agents for Alzheimer's, melatonin's transient neuroprotective effects in neonatal hypoxia, and sustainable healthcare technology. His work bridges clinical needs with cutting-edge imaging and nanotechnology. Leadership roles include directing strategic research areas at NTNU and coordinating national/international imaging infrastructures. His research has implications for improving diagnostics and therapies in neurology and oncology.

Michaelann TartisView profile

Professor

• Targeted drug delivery
• Ultrasound and microbubble technologies
• Lipid-based nanoparticles
• +3 more

Michaelann Tartis is a Professor at New Mexico Tech's Department of Chemical Engineering. Her research focuses on targeted drug delivery systems leveraging ultrasound and microbubble technologies, lipid-based nanoparticles, and advanced molecular imaging techniques for small animal studies. She specializes in developing validation methods for drug delivery systems and micro-encapsulation strategies. Her work bridges chemical engineering and biomedical applications, emphasizing controlled drug release mechanisms and biomaterial design. Research contributions include phospholipid prodrug conjugates, silica encapsulation methods, and hybrid nanobiomaterial synthesis using chemical vapor deposition techniques. Publications span topics like ultrasound-mediated drug delivery, liposome synthesis innovations, and cell encapsulation in silica matrices. Tartis has pioneered techniques for long-term cell viability studies in encapsulated systems and radiolabeled liposome development for medical imaging applications. No scientific awards are listed, though her extensive publication record reflects sustained research excellence. Her work integrates material science with biological systems to advance therapeutic delivery and diagnostic imaging capabilities.

Graeme F. WoodworthView profile

Professor

• Brain Tumor Research
• Therapeutic Ultrasound
• Nanomedicine
• +5 more

Graeme F. Woodworth, MD is the Howard M. Eisenberg, MD Distinguished Professor of Neurosurgery, Chair of the Department of Neurosurgery, and Director of the Brain Tumor Treatment and Research Center at the University of Maryland School of Medicine and University of Maryland Greenebaum Comprehensive Cancer Center. He leads a multidisciplinary team of neurosurgeons, radiologists, medical oncologists, and scientists focused on advancing brain tumor treatments through translational research and clinical innovation. Dr. Woodworth's educational background includes: Tufts University, BS, Chemistry, 1997 Johns Hopkins University School of Medicine, MD, 2005 Johns Hopkins Hospital, Intern, Surgery, 2006 Johns Hopkins Hospital, Resident, Neurosurgery, 2011 Johns Hopkins University School of Medicine, Fellow, Neuro-Oncology-NCI/Nanotechnology for Cancer Medicine Program, 2011 Weill Cornell Department of Neurological Surgery, Fellow, Cranial Neuro-Endoscopy, 2011 His research centers on three interconnected themes: Therapeutic Ultrasound development for blood-brain barrier disruption and drug delivery enhancement, Genetically-Engineered Models of glioma using transgenic rat systems, and Advanced Nanomedicine formulations for targeted brain tumor therapy. His work aims to transform glioblastoma from a uniformly fatal disease into a chronic condition through principles of maximal safe resection, intra-operative discovery, and targeted therapeutics for residual disease. Recent publications (2024-2025) demonstrate increasing integration of machine learning with focused ultrasound technology, expansion into brain metastasis treatment, and sophisticated nanoparticle engineering. Key trends include pivotal clinical trials (LIBERATE, LIMITLESS), closed-loop control systems for precision therapy, and multimodal approaches combining immunotherapy with blood-brain barrier modulation. Notable scientific awards include: Howard M. Eisenberg Distinguished Professorship (2023) Ferenc Jolesz Memorial Award (2022) Andrew J. Lockhart Memorial Prize (2019) Jorge Heller Outstanding Paper Award (2015) Research Scholar Award from American Cancer Society (2016) Multiple 'Top Docs' recognitions by Baltimore Magazine As department chair and center director, Dr. Woodworth oversees extensive research programs funded by NIH R01 grants, American Cancer Society awards, and Focused Ultrasound Foundation initiatives. His leadership drives multi-institutional collaborations including the ReSPOND consortium for glioblastoma research and clinical trials across 22 international sites. He mentors junior faculty and residents while directing the Translational Therapeutics Research Group's work on surgical outcomes registries for hydrocephalus, cerebrovascular disease, and spinal tumors. The Translational Therapeutics Research Group (TTRG) operates specialized facilities for in vivo brain tumor modeling, focused ultrasound applications, and nanomedicine characterization. Current initiatives include developing nestin-TV-A transgenic rat models for glioblastoma margin studies, optimizing MRI-guided focused ultrasound parameters for blood-brain barrier disruption, and engineering Fn14-targeted nanoparticles for precision drug delivery. The team collaborates closely with the University of Maryland Greenebaum Comprehensive Cancer Center's neuro-oncology program on first-in-human clinical trials.

• Neurosurgery
• Glioblastoma
• Therapeutic Ultrasound
• +5 more

Graeme Woodworth is a Professor and Chair of the Department of Neurosurgery at the University of Maryland School of Medicine , where he also serves as Director of the Brain Tumor Treatment & Research Center at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC). His work integrates clinical neurosurgery, translational research, and leadership in advancing therapies for brain tumors through innovative technologies like MRI-guided focused ultrasound and nanomedicine. He leads the Translational Therapeutics Research Group , bridging engineers, cancer biologists, and clinician-scientists to develop novel treatment paradigms. Education: Tufts University, BS, Chemistry, 1997 Johns Hopkins University School of Medicine, MD, 2005 Neurosurgery Residency, Johns Hopkins, 2011 Fellowships in Neuro-Oncology and Cranial Neuro-Endoscopy, 2011 Dr. Woodworth’s research focuses on therapeutic ultrasound to disrupt the blood-brain barrier (BBB) for enhanced drug delivery in glioblastoma, with clinical trials like LIBERATE and LIMITLESS under his leadership. His team’s work includes genetically engineered rat models for glioma studies, advanced nano-drug formulations targeting Fn14-positive tumors, and improving the safety and accuracy of neurosurgical interventions via outcomes registries. His publications highlight focused ultrasound , nanoparticle engineering , and translational neuro-oncology . Recent collaborations emphasize machine learning-based predictive models for tumor infiltration and recurrence, closed-loop ultrasound systems , and immunotherapy integration for CNS tumors. He has received numerous awards, including the Howard M. Eisenberg Distinguished Professorship (2023) and Elected Member of the American Society for Clinical Investigation (2025). His clinical expertise spans brain tumors, pituitary tumors, awake brain surgery, and spinal tumor resection.

• Physical Acoustics
• Functional Materials for Acoustics
• Contactless Micromanipulation with Acoustic Waves
• +9 more

Diego Baresch is a researcher at the University of Bordeaux specializing in Physical Acoustics and Functional Materials for Acoustics . His work focuses on contactless micromanipulation using acoustic waves, ultrasonic imaging, and modeling of complex wave propagation. Key research areas: Opto-acoustics, Nanophononics, Picosecond Biophononics Projects: ANR, PEPR, CARNOT, European collaborations Techniques: Acoustic trapping, Radiation force, Wavefront engineering His recent articles (2013-2025) demonstrate expertise in acoustical tweezers , microbubble dynamics , and spin-orbital angular momentum conversion . Publications address challenges in soft solid rheology, particle manipulation, and wave propagation in complex media. The work spans biomedical applications (e.g., targeted drug delivery) and fundamental wave physics. Diego contributes to multidisciplinary teams including DYNAMICS Mechanics, corrosion, hydrogen and Multiscale Modeling and Behavior of Heterogeneous Materials . He is active in the Cluster of Platforms I2M , working on metrology and characterization technologies.

• Microbubble dynamics
• Vascular drug delivery
• Sonoporation
• +4 more

Bram Meijlink is a Researcher at Erasmus MC in the field of Cardiology , focusing on advanced vascular drug delivery techniques using ultrasound-activated microbubbles. His work integrates molecular biology, biomedical imaging, and therapeutic delivery mechanisms. Research Interests : Microbubble dynamics in drug delivery Sonoporation-induced endothelial cell responses F-actin cytoskeleton disruptions Targeted delivery via pores and tunnels Biomedical imaging techniques (confocal microscopy) Scientific Trends : His recent publications (2022–2025) highlight innovations in microbubble engineering, sonoporation mechanisms, and transcellular delivery pathways. Key methodologies include confocal microscopy and in vitro/in vivo modeling.